The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 21, 2014
Filed:
Jan. 26, 2009
Masakazu Toi, Kyoto, JP;
Hiroji Iwata, Aichi, JP;
Katsumasa Kuroi, Tokyo, JP;
Seigo Nakamura, Tokyo, JP;
Shinji Ohno, Fukuoka, JP;
Norikazu Masuda, Osaka, JP;
Kenjiro Aogi, Ehime, JP;
Nobuaki Sato, Niigata, JP;
Futoshi Akiyama, Tokyo, JP;
Masafumi Kurosumi, Saitama, JP;
Hitoshi Tsuda, Tokyo, JP;
Masakazu Toi, Kyoto, JP;
Hiroji Iwata, Aichi, JP;
Katsumasa Kuroi, Tokyo, JP;
Seigo Nakamura, Tokyo, JP;
Shinji Ohno, Fukuoka, JP;
Norikazu Masuda, Osaka, JP;
Kenjiro Aogi, Ehime, JP;
Nobuaki Sato, Niigata, JP;
Futoshi Akiyama, Tokyo, JP;
Masafumi Kurosumi, Saitama, JP;
Hitoshi Tsuda, Tokyo, JP;
Japan Breast Cancer Research Group, Tokyo, JP;
Abstract
An administration method comprising: determining a cancer type through (i) first data indicating that an Estrogen Receptor (ER) is negative and a Human Epidermal growth factor Receptor-2 (Her2) is negative, or (ii) second data indicating that at least one of the ER and the Her2 is positive; and when the cancer type is determined through (i) the first data indicating that the ER is negative and the Her2 is negative: first performing a docetaxel administration cycle comprising administrating docetaxel to a patient multiple times at certain intervals; and then performing a 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) administration cycle comprising administrating 5-fluorouracil, epirubicin, and cyclophosphamide to the patient multiple times at certain intervals, and when the cancer type is determined through (ii) the second data indicating that at least one of the ER and Her2 is positive: first performing the FEC administration cycle; and then performing the docetaxel administration cycle.